Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16021723 | 0.88 | PGR (0.36) | PGR | |
| SCHEMBL4094054 | 0.83 | PGR (0.31) | PGR | |
| SCHEMBL22971284 | 0.83 | — | — | |
| SCHEMBL13163185 | 0.83 | KDM1A (0.30) | PGR | |
| SCHEMBL4828130 | 0.83 | PGR (0.31) | PGR | |
| SCHEMBL24988840 | 0.83 | — | — | |
| SCHEMBL9823614 | 0.79 | — | — | |
| SCHEMBL10208324 | 0.79 | FFAR2 (0.30) | — | |
| SCHEMBL20098077 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL12302888 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| WO-2024126117-A1 | PYRIMIDINONE DERIVATIVES AS PESTICIDAL COMPOUNDS | BASF SE (DE) | 2024-06-20 | — | — | WO | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230348456-A1 | QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2012-12-27 | — | — | US | disclosed |
| US-8093254-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-7880009-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; (E)-N-biphenyl-3-ylmethyl-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)acrylamide for example; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20100069406-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100016341-A1 | ASPARTYL PROTEASE INHIBITORS CONTAINING A TRICYCLIC RING SYSTEM | SCHERING CORPORATION | 2010-01-21 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| WO-2007087488-A9 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| WO-2007087488-A2 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | PGR 4728/4885 |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | PGR 3076/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | PGR 4144/4885 |
| US-20100016341-A1 | ASPARTYL PROTEASE INHIBITORS CONTAINING A TRICYCLIC RING SYSTEM | PRSS1, PRSS3, BACE1 | PGR 2022/4885 |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | ERAP1, CHP1, QSOX1 | PGR 2313/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | PGR 1219/4885 |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | DGKG, DGKA, DNER | PGR 2835/4885 |
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MAPK15, CDK15, MAPKAPK5 | PGR 1531/4885 |
| US-20230348456-A1 | QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK1G3 | PGR 3946/4885 |
| US-20100069406-A1 | ASPARTYL PROTEASE INHIBITORS | BACE1, CHRM1, CHRM2 | PGR 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.